Phoenix Biotech Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Phoenix Biotech Acquisition (PBAXU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Phoenix Biotech Acquisition's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - | - | Yes |
| Competitors combined (66) | ||||
| High-Confidence Competitors (3) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PBAXU Stock Performance relative to its Competitors
PBAXU Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Jasper Therapeutics Inc | 282.9% | Outperformed |
| 3 | Century Therapeutics inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Phoenix Biotech Acquisition's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Phoenix Biotech Acquisition's Comment on Competition and Industry Peers
Publicly Traded Peers of Phoenix Biotech Acquisition Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Phoenix Biotech Acquisition Corp |
437.35 | - |
 Amgen Inc |
255,014.76 | 38,903.00 |
 Gilead Sciences Inc |
210,105.45 | 30,988.00 |
 Vertex Pharmaceuticals Inc |
138,476.62 | 12,951.60 |
 Gsk Plc |
104,242.44 | 43,093.89 |
 Regeneron Pharmaceuticals Inc |
100,445.66 | 16,896.20 |
| SUBTOTAL | 1,092,602.07 | 170,025.13 |
Sign in to see all competitors of Phoenix Biotech Acquisition Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Phoenix Biotech Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Phoenix Biotech Acquisition's Competitors Named by the Company
Competitive relationships identified from Phoenix Biotech Acquisition reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| TScan Therapeutics Inc. | Company report | 85% |
| TCR2 Therapeutics Inc. | Company report | 85% |
| Adaptimmune Therapeutics, plc | Company report | 85% |
| MediGene AG | Company report | 85% |
| Adaptive Therapeutics, Inc. | Company report | 85% |
| Ziopharm Oncology, Inc. | Company report | 85% |
| 3T Biosciences, Inc. | Company report | 85% |
| Immatics, N.V. | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Century Therapeutics inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Phoenix Biotech Acquisition's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Phoenix Biotech Acquisition's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.43 % |
| Exelixis Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | 437 | - | - |
| Amgen Inc | 255,015 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 210,105 | 1,822,824 | -227,235 |
| Vertex Pharmaceuticals Inc | 138,477 | 31,979,259 | 9,817,037 |
| Gsk Plc | 104,242 | 169,660,977 | 32,662,867 |
| Regeneron Pharmaceuticals Inc | 100,446 | 1,096,444 | 312,615 |
| PEERS TOTAL | 1,092,165 | 2,313,110 | 211,675 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Illumina Inc | United States and Canada 56.42 % |
| Exelixis Inc | United States 92.47 % |
| Immunitybio inc | United States 99.79 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Phoenix Biotech Acquisition's industry classification, broader than the peer set above. Market cap in millions of $.Phoenix Biotech Acquisition ranks #0 of 157 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,443, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 254,081 | 27.22 % |
| 2 | Gilead Sciences Inc | 208,762 | 22.37 % |
| 3 | Moderna Inc | 92,077 | 9.86 % |
| 4 | Argenx Se | 64,796 | 6.94 % |
| 5 | Biogen Inc | 1,234 | 5.2% |
| 6 | Revolution Medicines Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 0 | Phoenix Biotech Acquisition Corp | 298 | 0.00 % |
Market cap and industry share for the rest of Phoenix Biotech Acquisition's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2024-02-07.
Phoenix Biotech Acquisition's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Phoenix Biotech Acquisition's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,443 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Phoenix Biotech Acquisition's dedicated Suppliers and Customers pages, not here.
Phoenix Biotech Acquisition's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (63.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Phoenix Biotech Acquisition's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | 0.04 | 0.14 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Phoenix Biotech Acquisition's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | +9.6 % | +53.5 % |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Phoenix Biotech Acquisition's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Phoenix Biotech Acquisition's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - |
| Amgen Inc | 27.08 | 6.56 |
| Gilead Sciences Inc | - | 6.78 |
| Vertex Pharmaceuticals Inc | 34.99 | 10.69 |
| Gsk Plc | 13.83 | 2.42 |
| Regeneron Pharmaceuticals Inc | 21.04 | 5.94 |
| PEERS AVERAGE | 70.42 | 6.43 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.